Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.

已完结 10 由 Semaglutide 发布于 2026/6/3 13:29:47

DOI:10.1056/nejmoa2511774
作者：Sean Wharton,Louis J Aronne,Adam Stefanski,Nasreen F Alfaris,Andreea Ciudin,Koutaro Yokote,Bruno Halpern,Alpana P Shukla,Chunmei Zhou,Lisa Macpherson,Sheryl E Allen,Nadia N Ahmad,Suzanne R Klise,
文献类型：期刊论文
补充材料：只需要正文

New England Journal of Medicine (NEJM)

Abstract：BACKGROUND Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. METHODS In this phase 3, m

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Revisiting active sites for nitrogen reduction reaction on 2D materials supported metal atoms: A theoretical investigation